Other stories

Thursday, August 5, 2010

Arthritis patients 'may benefit from weight training'

A regular weight training regime may help treat rheumatoid arthritis, research suggests.

A study of 28 patients funded by Arthritis Research UK found those who pumped iron saw improvements in basic physical function, such as walking.

Researchers at Bangor and Gwynedd Hospital said such high intensity exercising could play a key role alongside drug treatment.

Experts said the exercise regime would not be appropriate for all patients.

RA is mainly a disease affecting the joints, but a less well known symptom is that it also severely reduces muscle mass and strength and this occurs even among patients whose disease is well managed.

Those with the condition are often given mild home exercises to do to stop their joints stiffening and becoming painful.

Weight training

To test how effective the weight training was the researchers split the 28 participants into two groups, the Arthritis Care and Research journal reported.

One did regular weight training for 24 weeks, while the others did the less strenuous standard home exercise regimes.

They found physical function improved by between 20% to 30% in the group doing weight training. Strength also increased by nearly 120%.

The high intensity training was found to increase the levels of an insulin-like growth factor (1GF-1) and insulin-like growth binding protein 3 - both of which promote the growth of muscles, bone and cartilage.

Study leader Dr Andrew Lemmey said muscle loss was a major contribution to the disability associated with the condition.

"Lifting, carrying, walking, climbing stairs are impaired.

"It is logical that if you can restore muscle, that strength and consequently functional capacity will also be restored. And this is what we have found."

He said the patients, who were mainly women in their 50s and had the disease for up to a decade, had responded well.

"In fact, the improvements in function were so significant that following training these patients with established RA were performing as well as or better than healthy individuals of the same age and sex."

He said he would like to see this sort of high intensity treatment funded along with drug therapies, but said that a multi-centre trial would be needed before this could be agreed and that they had received no funding for this.

Benefits were thought to be lost four to eight months after training ended.

A spokesman for Arthritis Research UK said: "Weight-training, especially at this level, is not for everyone with rheumatoid arthritis, but for those who are very well-motivated and physically able, we have proved that it can dramatically improve muscle strength and tone."

A spokesman for the National Rheumatoid Arthritis Society agreed, but urged caution.

"Of course RA can affect different people in very different ways so pumping iron may not be appropriate for everyone. People should discuss [this] with their physio."

source;
www.bbc.co.uk

IPO Market on the 'Horizon'? Another Firm Files to Go Public

Published August 5, 2010

While bankers and other Wall Street observers debate whether the initial public offering window really has opened for the industry, specialty pharma firm Horizon Pharma Inc. stepped up with its own filing for a proposed $86 million IPO.

Horizon's move came only a day after Trius Therapeutics Inc. managed to squeeze through the window – albeit with fewer shares and a lower price than originally hoped – netting about $45.6 million to support its late-stage antibacterial program. A day after its debut, Trius' stock (NASDAQ:TSRX) gained 9.4 percent, or 47 cents, closing Wednesday at $5.47.

And NuPathe Inc., of Conshohocken, Pa., is expected to price its offering of 5 million shares this week. That firm, which anticipates using proceeds on commercialization activities related to its transdermal sumatriptan product, Zelrix, recently set a price range between $14 and $16 per share. (See BioWorld Today, May 18, 2010.)

So far this year, eight companies have succeeded in pricing IPOs, starting with Ironwood Pharmaceuticals Inc.'s February offering – hailed as a major victory among biotech circles following the IPO desert of 2008 and most of 2009. Though Ironwood wasn't exactly followed by a flood of newly listed firms, there has been a steady trickle, with even a few more true biotechs with development-stage programs such as Anthera Pharmaceuticals Inc., AVEO Pharmaceuticals Inc. and Tengion Inc. hitting the public markets. (See BioWorld Today, March 2, 2010, March 15, 2010, and April 12, 2010.)

While Horizon falls more on the specialty pharma side, it's still not looking at its first FDA approval until early next year at the earliest. The Northbrook, Ill.-based firm, which has not yet disclosed the number of shares or share price for its proposed IPO, is hoping to use those proceeds for regulatory and commercial activities related to its gastrointestinal-friendly pain products.

HZT-501, a combination of nonsteroidal anti-inflammatory drug ibuprofen plus famotidine, is under FDA review, with a PDUFA date of Jan. 21, 2011. That drug is designed to treat mild to moderate pain, osteoarthritis and rheumatoid arthritis pain while reducing the risk of NSAID-induced upper GI ulcers.

Horizon isn't the only firm to work on safer NSAIDs. Earlier this year, Pozen Inc. and partner AstraZeneca plc won approval for their combination naproxen-esomeprazole arthritis drug Vimovo. Another naproxen-based drug, naproxcinod from NicOx SA, however, failed to get the FDA's OK last month. (See BioWorld Today, May 3, 2010, and July 23, 2010.)

Earlier in its pipeline, Horizon also is working on a naproxen combo drug, HZN-602, which is in Phase I testing for mild to moderate pain and arthritis pain.

But shortly behind HZT-501, Horizon has Lodotra, a programmed-release formulation of low-dose prednisone acquired in the April merger with Merck KGaA spinout firm Nitec Pharma AG, of Reinach, Switzerland. That program yielded positive Phase III data, and the company anticipates a fourth quarter new drug submission. (See BioWorld Today, April 2, 2010.)

Horizon, which was founded in 2005, had about $28.5 million in cash as of March 31. As of June 30, the firm had about 29.8 million shares outstanding.

Jefferies & Co. Inc. and Piper Jaffray & Co. are acting as joint book-running managers, while JMP Securities LLC and Lazard Capital Markets LLC are serving as co-managers for the offering.

If successful, Horizon plans to list on Nasdaq under the ticker "HZNP."

In other financings news:

• ALDA Pharmaceuticals Corp., of Vancouver, British Columbia, is seeking an extension of the exercise period of an aggregate of 6 million outstanding share purchase warrants issued as part of the nonbrokered private placement of common share units which closed Sept. 16, 2009. It would extend the exercise price for one more year, until Sept. 16, 2011, though the warrant exercise price of 40 cents per share will remain the same.

• Gemin X Pharmaceuticals Inc., of Malvern, Pa., completed an $8 million Series E round, with participation from preferred stockholders Caxton Advantage Life Sciences Fund LP and Sanderling Venture Partners. The firm is exploring strategic opportunities for lead candidate obatoclax, a pan Bcl-2 inhibitor that recently showed promising Phase IIb data in small-cell lung cancer.


source;
www.bioworld.com

Scientists discover new drug target for immune diseases

Scientists have found a new mechanism that explains how certain immune cells are activated to create protective antibodies against infections or pathological antibodies such as those present in autoimmune diseases like lupus and rheumatoid arthritis.

Led by Dr. Andrea Cerutti, MD, Professor of Medicine at Mount Sinai School of Medicine, researchers studied human tissue and immune cells from people with mutations of TACI and MyD88, two proteins required to activate the immune system.

MyD88 is a signaling protein that alerts the so-called innate immune system. TACI is a receptor protein used to activate immune cells in the so-called adaptive immune system.

"Our research shows that TACI and MyD88 are part of an immune circuit that bridges the innate and adaptive immune systems. This circuit makes our immune response more flexible, allowing a more effective generation of protective antibodies during infections.

Genetic defects of TACI and MyD88 cause immunodeficiencies characterized by recurrent, life-threatening infections. On the other hand, an abnormally strong TACI-MyD88 interaction may exacerbate autoimmune diseases like lupus or rheumatoid arthritis," said Dr. Cerutti, lead investigator of the study.

"Previous studies had suggested an involvement of TACI and MyD88 in lupus. Now that we have identified this interaction, we can figure out a way to inhibit it and prevent these diseases from getting worse."

Autoimmune diseases like lupus and rheumatoid arthritis are characterized by exaggerated production of molecules that activate the adaptive immune system and abnormal antibodies, which attack normal cells causing inflammation and tissue damage. This exaggerated production may occur partly as a result of abnormally strong signaling from TACI via MyD88.

By analyzing cells and tissues from immunodeficient patients and genetically engineered mice, Dr. Cerutti's team found a previously unknown interaction between TACI and MyD88 that is important for the production of antibodies against infectious agents. Yet, the same interaction may cause the exaggerated immune response in people with autoimmune diseases.

"Our discovery provides a novel specific target, the signaling pathway between TACI and MyD88, to block the overreaction of the immune system and tissue damage in individuals with autoimmune disorders," said Dr. Cerutti. "We look forward to studying this discovery further and developing therapeutic targets that will inhibit the interaction between TACI and MyD88, preventing autoimmune diseases from progressing with fewer side effects than currently prescribed treatments."

The research is published online in the September issue of Nature Immunology. (ANI)

source;
www.dnaindia.com

ARTHRITIS Get Moving (Gently) to Help Ease, Prevent Pain

Alcohol offers protection, relief from rheumatoid arthritis

Drinking alcohol regularly may not be too bad for the health, at least for rheumatoid arthritis sufferers or those at high risk of acquiring the painful condition.

A study by British researchers showed that non-drinkers were more prone to developing the debilitating condition than those who drank alcohol more than 10 days per month.

The study by researchers in Sheffield, England published recently in the U.K. journal Rheumatology also indicate that alcohol alleviates the symptoms of RA.

The research involved the comparison of 873 rheumatoid arthritis patients with 1,004 non-RA sufferers. All participants underwent blood tests and X-ray and joint examination. They also answered a questionnaire on alcohol use.

Results of the exams showed that the drinkers had less damage to their joints, low levels of inflammation of joints, and lesser joint pain, swelling and disability compared to the non-drinkers, according to James Maxwell, a rheumatologist at the Rotherham Foundation NHS Trust and author of the study.

The less severe RA symptoms among drinkers were attributed to the alcohol's blunting effect on the immune system, though the study emphasized that this suspicion is still subject to confirmation through more research.

An autoimmune disease, the immune system of an RA sufferer attacks the tissues lining the joints or synovium causing inflammation and tissue overgrowth. The condition is untreatable and symptoms can only be alleviated through nutrition, drug therapy, supplements, and exercise.

There are an estimated 21 million people who suffer from RA worldwide.